A B S T R A C T Although congenital adrenal hyperplasia due to 3P-hydroxysteroid dehydrogenase deficiency generally reveals a predominance of A5-3P-hydroxysteroids, on occasion substantial quantities of pregnanetriol have been found as well. It appears that the latter steroid more often occurs in the subjects who have survived beyond infancy. The use of the measurement of pregnanetriol alone may therefore not be relied upon as a sole determinant of the specific form of defective steroidal biogenesis. It is more characteristic of the 21-hydroxylase deficiency. However when both A5-pregnenetriol and pregnanetriol are measured the ratio of the former to the latter is always considerably below 1.0 in 21-hydroxylase deficiency and always above 1.0 in 3,8-hydroxysteroid dehydrogenase. Furthermore, 1l-ketopregnanetriol has been found only in the urine of subjects with the 21-hydroxylase deficiency. Thus, these two forms of defective steroidal biogenesis may be distinguished by the measurement of these three urinary steroidal metabolites. (5,8-pregnane-3a ,17a, 20a-triol) ; A5-pregnenetriol, (preg-5-ene-3p6,17a,20a-triol); 11-ketopregnanetriol, (3a,17a,20a-trihydroxy-5,3-pregnan-11-one); dehydroepiandrosterone, (3,8-hydroxyandrost-5-en-17-tities of pregnanetriol in the urine in addition to the assortment of A5-3P-hydroxysteroids characteristic of this condition (1) . At the time, it was believed that this single instance might represent a double enzyme defect involving the 21-hydroxylase (21-H) as well. However, it is to be noted that a second case in this original series also excreted pregnanetriol in small quantities (1) . More recent reports of further instances of HSD deficiency with the expected basic pattern of z5-3l8-hydroxysteroids in the urine also include patients who excreted substantial quantities of pregnanetriol (2-5). On examining the assortment of reported cases, it appears that older subjects more often excrete pregnanetriol. In our original study most patients were infants. A double enzyme defect in this increasing number of cases now seems unlikely. The matter has been reinvestigated by examining the urines of 16 subjects with 21-H and 9 with HSD deficiency with particular attention to the urinary metabolites, A'-pregnenetriol, pregnanetriol, and 11 -ketopregnanetriol. One of the purposes of this study was to find a criterion based on these metabolites for the clear delineation of the two types.
INTRODUCTION

METHODS
Urines were obtained before the initiation of any treatment and stored at -10'C. The subjects and their ages are listed in Table I . Portions of 10-25 ml were sequentially hydrolyzed by mammalian glucuronidase and solvolysis as described earlier (1) . After extraction, the products of each method of hydrolysis were examined separately. The extracts were partially purified before gas-liquid chromatography (GLC) as follows. ples of pregnanetriol and pregnenetriol extracted from water and run through the entire procedure 10 times was 87 +5%.
Two adult normal male volunteers were given 50-60 mg of 17a-hydroxypregnenolone (1 mg/kg body weight) orally. Two 24-hr urine collections were obtained before and three after the administration of the steroid.
RESULTS
The findings in subjects with congenital adrenal hyperplasia are shown in Table I and Fig. 1L2 The excretory products found in the two normal human volunteers studied are indicated in Fig. 2 .
Although most of the pregnanetriol and 11-ketopregnanetriol were present in the fraction released by glucuronidase and the A5-pregnenetriol in that released after solvolysis, there was overlap in some instances. Pregnanetriol and 11-ketopregnanetriol predominate in 21-H deficiency in all instances although occasionally respectable but considerably smaller amounts of A5-pregnanetriol were found. In HSD deficiency pregnanetriol was found, at times in large quantity, usually in the older subjects. Nonetheless when the results are expressed as ratios of pregnenetriol/pregnanetriol as shown in Fig. 1 there is no overlap between these two forms of the disorder and it is possible to distinguish them on this basis. The ratio is well below 1 It is probable that pregnanetriol arises from peripheral extra-adrenal conversion of A5-3P-hydroxysteroids in HSD deficiency. A likely precursor for such a transaction is 17a-hydroxypregnenolone. In two normal subjects the administration of this compound led to the excretion of more pregnanetriol than A5-pregnenetriol and it is likely that the conversion occurred in extra-adrenal sites. Fukushima, Bradlow, Hellman, and Gallagher (6, 7) provided evidence that urinary pregnanetriol arose from 17a-hydroxypregnenolone in a subject with metastatic adrenal carcinoma, and further showed that a normal subject excreted substantial quantities of pregnanetriol which was derived from the administration of isotopically labeled 17a-hydroxypregnenolone. Roberts , Vande Wiele, and Lieberman (8) have provided similar evidence in a patient with an adrenal adenoma. Fotherby and Love (9) have also noted the conversion of administered nonisotopic 17a-hydroxypregnenolone to urinary pregnanetriol in five human subjects. Our results reveal an even greater conversion to pregnanetriol than was reported in these other studies. We administered the precursor orally whereas the others did so intravenously. This suggests that the liver may be the extraadrenal site of conversion perhaps through hepatic 3,8-hydroxysteroid dehydrogenase which may be under genetic control different from that of the adrenals. These extra-adrenal enzymes may mature slowly after birth so that the observation of elevated urinary pregnanetriol in HSD deficiency is to be more commonly found after infancy.
